Advancements in ALS Treatment

This chapter explores the ATLAS study on early intervention strategies for ALS patients with genetic mutations, highlighting the significance of biomarkers like neurofilament light chain levels. It discusses the cautious optimism surrounding new treatments, particularly Tofersen, and the ongoing evolution of ALS as a treatable condition.